AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 10.99 |
Market Cap | 680.80M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.8 |
PE Ratio (ttm) | -14.02 |
Forward PE | n/a |
Analyst | Buy |
Ask | 11.5 |
Volume | 753,639 |
Avg. Volume (20D) | 1,253,977 |
Open | 11.24 |
Previous Close | 11.12 |
Day's Range | 10.98 - 11.42 |
52-Week Range | 2.89 - 13.85 |
Beta | undefined |
About CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical setting...
Analyst Forecast
According to 6 analyst ratings, the average rating for CRMD stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 42.60% from the latest price.
Next Earnings Release
Analysts project revenue of $19.79M, reflecting a n/a YoY growth and earnings per share of 0.05, making a -119.23% decrease YoY.
2 months ago · seekingalpha.com
Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital +The 'Undercovered' Dozen highlights 12 lesser-covered stock ideas from October 18th - 24th, offering fresh investment takes for community discussion. Dnis Buivolov updates their Nebius Group valuation...